MedTrace Logo

Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System

NCT04860895 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4400

Last updated 2021-05-06

No results posted yet for this study

Summary

The aim of this research is to use the Multi-Spectral method to measure the biomolecular fingerprint of the virus directly instead of the virus's RNA (RT-PCR) or the body's immune response (antibody) measurement methods to diagnose the SARS-COV-2 virus, thereby determining whether COVID-19 can be diagnosed faster, cheaper and without requiring a medical laboratory environment.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

AP-23

AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.

Sponsors & Collaborators

  • Fable Biyoteknoloji San ve Tic A.S

    lead INDUSTRY

Principal Investigators

  • İsmail Tayfur, MD · Sancaktepe Şehit Prof.Dr. İlhan Varank Training and Research Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-11
Primary Completion
2021-05-01
Completion
2021-05-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04860895 on ClinicalTrials.gov